Academic Journal
View in EDS

Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial

Bibliographic Details
Title: Switch to fixed-dose doravirine (100 mg) with islatravir (0·75 mg) once daily in virologically suppressed adults with HIV-1 on antiretroviral therapy: 48-week results of a phase 3, randomised, open-label, non-inferiority trial
Authors: Molina, Jean-Michel, Rizzardini, Giuliano, Orrell, Catherine, Afani, Alejandro, Calmy, Alexandra, Oka, Shinichi, Hinestrosa, Federico, Kumar, Princy, Tebas, Pablo, Walmsley, Sharon, Grandhi, Anjana, Klopfer, Stephanie, Gendrano, Isaias, Eves, Karen, Correll, Todd A, Fox, Michelle C, Kim, Jason *
Source: In The Lancet HIV June 2024 11(6):e369-e379
Database: ScienceDirect
More Details
ISSN:23523018
DOI:10.1016/S2352-3018(24)00031-6
Published in:The Lancet HIV
Language:English